SBIR/STTR Research Award

Continuous measurement of cell growth as an optimal tool in drug toxicity testing (Supplement)

Award identifier 1607c69a4678e68bd53a85da663c54330b79cfde08efa952f5874a255c7721d7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$273,503

Program and phase

STTR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EnTox Sciences LLC
Proposal award date
2015-04-01
Contract end date
2017-02-28
UEI
KKT9PGKVV2A1
Solicitation number
PA14-077
Topic code
NCATS

Research abstract

DESCRIPTION provided by applicant During the process of screening for drugs with therapeutic potential often times several candidates emerge as prime candidates with similar efficacy and the choice for a lead compound is difficult to make However peopleandapos s lives and billions of dollars may rest on the choice of which compound to bring to clinical investigation and trials Since any levels of toxicity caused the by drug would contra indicate its choice as a lead compound detection of very low level toxicity could form the basis for ranking such groups of compounds in an objective fashion Accordingly the overall goal of the proposal is to build an algorithm relating a novel ultra sensitive in vitro measure of toxicity to clinical toxicity whichwill be used to rank candidate drugs being considered as lead compound of clinical trials We reasoned that even a very slow rate of cell death induced by a chronically administered drug might over the years kill off a significant proportion of an organ or cell type However a change in cell number of only a few percent is below the detection limit of current in vitro tests We hypothesize that some side effects of drugs occurring in vivo could be revealed in in vitro tests if they were sensitive enough We have established unique methods to measure cell number and metabolic viability as reflected by continuous measurement of oxygen consumption with the required sensitivity The key to establishing the utility of our approach will be to demonstrate strong correlation with in vivo safety and toxicology using a relevant panel of benchmark compounds about which prior in vivo data is well known and that contains a spectrum from highly andquot safeandquot drugs to those with known toxicity We will optimize methods to measure small changes in oxygen consumption a measure of cell number in various selected cell types and verify the methods by testing with compounds that have varying degrees of toxicity This will lay the foundation for the eventual construction of an objective algorithm that can be used to rank the potential of lead compounds on the basis of toxicity caused by chronic administration PUBLIC HEALTH RELEVANCE The research will involve the development of novel methods to reveal very low levels of drug toxicity These methods are aimed at meeting the needs of pharmaceutical companies who wish to avoid bringing drugs to market that have unexpected side effects after many years of chronic administration Successful validation of the approach will be followed by marketing and licensing by our recently formed company EnTox Sciences LLC

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $1,555,355. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.